What Happens After a Positive Urinary Biomarker Result? Cystoscopy, Imaging and Repeat Testing

The message lands in the patient portal on a Tuesday afternoon: “Urine tumor marker: positive. Please schedule a follow-up.” No explanation, no context, just two words that seem to weigh more than the whole rest of the screen. By the time the phone rings the next morning, most people have already read a dozen web pages and slept badly.

Here is the thing those pages rarely say plainly. A biomarker is a clue, not a verdict. Urine is a busy fluid, and the proteins, cells and DNA fragments that these tests look for can be nudged upward by an infection, a kidney stone, a recent catheter, an enlarged prostate or simply the test’s own margin of error. So the honest question is not “do I have cancer?” but “what are the positive urine biomarker next steps that will actually settle this?”

That is what this explainer walks through: which tests come next, why they are ordered in a particular sequence, who is usually fast-tracked and who is asked to wait, and what the weeks in between tend to look like.

Positive urine biomarker next steps: what the result really tells you

A biomarker is any measurable substance in the body that hints at a process going on inside it. In urine, the biomarkers used in urology are mostly proteins shed by cells, abnormal cells themselves, or fragments of DNA and RNA carrying changes seen in tumors. A “positive” result means the lab found more of that substance than a preset cut-off. It does not say where the substance came from, whether the source is cancerous, or whether it matters at all.

Think of a smoke detector. It goes off for burnt toast as readily as for a house fire, and nobody would call the fire department without first looking around the kitchen. In urine testing, the “looking around” is done with a camera, a scan and a second sample. Guidelines from the American Urological Association make the same point in more formal language: urinary biomarkers should not be used in place of cystoscopy when a person is first being evaluated for blood in the urine, because the markers are not reliable enough on their own to rule cancer in or out (see the PubMed reference to the AUA microhematuria guideline).

That guideline position shapes everything that follows. Whatever prompted the biomarker test in the first place, whether visible blood in the urine, microscopic blood found on a routine check, or surveillance after previous bladder cancer, a positive result moves you onto a pathway built around three tools:

• Direct inspection of the bladder lining (cystoscopy).
• Imaging of the parts the camera cannot reach, chiefly the kidneys and ureters.
• Repeat and complementary urine tests, especially cytology, which examines actual cells under a microscope.

Which of the three you need, and how quickly, depends on your personal risk profile rather than the biomarker number alone. The next sections unpack each piece, starting with what these tests are and are not measuring.

What is a urine biomarker test, and what is it looking for?

Most people meet urine testing first through the humble dipstick: a plastic strip with colored pads that change when they touch blood, protein, glucose, nitrite or white-cell enzymes. That is biomarker testing in its simplest form. The tests that generate a “positive tumor marker” alert are a generation more sophisticated, but they rest on the same logic: something the body would not normally excrete, or would excrete only in small amounts, is present above a threshold.

Broadly, urologic urine biomarker tests fall into four families.

• Cell-based tests. Urine cytology, in which a pathologist looks at cells washed out of the urinary tract and grades how abnormal they appear. MedlinePlus describes it as a screen for cancer and other conditions of the urinary tract, noting it is often paired with cystoscopy rather than used alone.
• Protein-based tests. These detect proteins such as nuclear matrix protein 22 or bladder tumor antigen, which are released in greater amounts when urothelial cells (the lining cells of the bladder and ureters) are dividing rapidly or breaking down.
• Chromosome and DNA tests. Fluorescence in situ hybridization (FISH) looks for extra copies of particular chromosomes inside urine cells; newer panels look for methylation patterns or mutations in tumor-associated genes.
• RNA panels. These measure messenger RNA from several genes at once and combine the readings into a score. For the prostate, a marker called PCA3 works this way.

What unites them is that each was designed to be sensitive, meaning it catches most real disease, at the price of specificity, meaning it also flags a fair number of people who turn out to be fine. That trade-off is deliberate. A screening or triage test that misses cancers is more dangerous than one that sends some healthy people for a camera check. It also explains why a positive result on its own cannot end the conversation.

What are some common biomarkers found in urine?

Patients often assume “biomarker” means “cancer test.” In practice, the markers most frequently measured in urine have nothing to do with tumors, and it helps to know which category your result belongs to before deciding how worried to be.

Everyday markers on a standard urinalysis. Red blood cells (hematuria), white blood cells and leukocyte esterase (an enzyme from white cells), nitrite (produced by many bacteria), protein or albumin, glucose, ketones, and specific gravity, which reflects how concentrated the urine is. These are the workhorses of primary care and emergency medicine.

Kidney-function markers. The urine albumin-to-creatinine ratio is the standard measure of early kidney damage in diabetes and high blood pressure; creatinine itself is used to normalize other results. Casts, which are tiny cylindrical clumps of cells or protein seen under the microscope, point toward specific kidney conditions.

Inflammation markers. White cells and leukocyte esterase are the most common. Research settings also measure proteins such as neutrophil gelatinase-associated lipocalin (NGAL) or kidney injury molecule-1, which rise early in acute kidney injury, though these remain largely investigational in routine care and should be described as such.

Tumor-associated markers. The cell, protein, chromosome and RNA tests outlined in the previous section. These are the ones that generate the “positive” alert this article is about.

Two things follow from this list. First, a positive on an inflammation marker such as leukocyte esterase usually points to infection and is investigated with a urine culture, not a cystoscopy. Second, inflammation and tumor markers interact: an active infection can raise several tumor-associated markers at the same time, which is one reason clinicians frequently treat or exclude infection before repeating a positive tumor marker. If your portal shows a positive result, the first useful question to ask is simply which kind of marker it was.

What diseases and cancers can biomarkers in urine detect?

Urine touches almost every part of the urinary tract on its way out, and it carries filtered traces of the bloodstream too. That makes it a useful, if imperfect, window onto several organ systems.

Infection. Nitrite, leukocyte esterase and white cells on a dipstick, confirmed by culture, remain the mainstay for diagnosing urinary tract infections.

Kidney disease. Albumin in the urine is one of the two pillars of chronic kidney disease staging (the other is the blood-based estimated glomerular filtration rate). Protein in the urine during pregnancy is a key sign of preeclampsia. Blood and casts help distinguish inflammatory kidney conditions from problems lower down.

Metabolic conditions. Glucose and ketones in urine were historically how diabetes was detected and are still useful in some emergency settings, though blood tests have largely taken over.

Cancers of the urinary tract. Bladder cancer is the main target. Because the bladder lining, the ureters and the kidney’s collecting system share the same urothelial cell type, cancers anywhere along that tract can shed cells and DNA into urine. Kidney cell cancers (renal cell carcinoma), which arise from a different cell type, shed far less and are mostly found by imaging rather than urine testing.

Prostate cancer. Prostate cells and RNA enter urine, especially after a digital rectal examination, and a handful of RNA-based urine tests are used alongside the blood PSA (prostate-specific antigen) test to help decide whether a biopsy is warranted. These tests estimate risk; they do not diagnose.

Notice what is missing. Urine biomarkers are not validated tools for detecting most other cancers, despite what some direct-to-consumer marketing implies. Where the evidence is limited or preliminary, a careful clinician will say so, and you should expect that honesty rather than a promise that a single sample can screen for “everything.”

Why a urine biomarker false positive is more common than people expect

A false positive is a test that flags disease in someone who does not have it. Every biomarker test produces some, and urine tests produce more than most because urine is exposed to so many ordinary irritants before it reaches the lab.

The mechanisms are worth understanding, because they often point to an easy explanation for your own result.

• Infection and inflammation. White cells and damaged lining cells release proteins that several tumor-marker assays cannot distinguish from tumor-derived proteins. Cytology can also read inflamed cells as “atypical.”
• Stones. A kidney or bladder stone scrapes the lining as it moves, shedding cells and blood.
• Recent instrumentation. A catheter, a cystoscopy or a prostate biopsy in the preceding weeks disturbs the urothelium and can raise markers for a while.
• Benign prostate enlargement. Common in men over 50, it causes bleeding and cell shedding that mimic more serious findings.
• Previous treatment. Chemotherapy or immunotherapy instilled directly into the bladder, and pelvic radiation, both alter cells in ways that can look abnormal for months.
• Sample handling. Very dilute urine, delayed processing or a sample taken during menstruation can all distort results.

None of this means a positive result should be shrugged off. It means the appropriate response is to check rather than to assume. The AUA microhematuria guideline builds this in: it advises that blood in the urine attributed to a benign cause such as infection should be re-tested once that cause has been treated, and only if the abnormality persists does the full evaluation proceed. A similar logic applies to tumor markers. If your clinician asks for a repeat sample after treating an infection, that is not delay for its own sake; it is the quickest way to remove the commonest confounder before subjecting you to a camera and a scan you may not need.

Who is fast-tracked to cystoscopy after an abnormal urine test, and who is asked to wait?

This is where the pathway stops being one-size-fits-all. The AUA microhematuria guideline sorts adults into low, intermediate and high risk for urinary tract cancer using a small number of factors, and the workup differs by tier. Although the guideline was written for blood in the urine rather than for tumor markers specifically, urologists commonly apply the same risk logic when deciding what a positive biomarker should trigger.

Risk tier (AUA microhematuria guideline)	Typical profile	Usual initial approach
Low	Women under 50 or men under 40; never smoked or fewer than 10 pack-years; 3–10 red cells per high-power field; no other risk factors	Shared decision: repeat urinalysis in about 6 months, or proceed to cystoscopy plus kidney ultrasound
Intermediate	Women 50–59 or men 40–59; 10–30 pack-years; 11–25 red cells per high-power field; or another risk factor	Cystoscopy plus kidney ultrasound
High	Age 60 or over; more than 30 pack-years; more than 25 red cells per high-power field; or any episode of visible blood	Cystoscopy plus CT urography

A pack-year is one pack of cigarettes a day for one year; 20 pack-years could be one pack a day for 20 years or two packs a day for 10. Smoking is the single most important modifiable risk factor for bladder cancer, which is why it weighs so heavily in the table.

Other factors that push people toward earlier cystoscopy include long-term exposure to certain industrial chemicals, a history of pelvic radiation, chronic bladder irritation from an indwelling catheter, a family history of urothelial cancer, and irritative symptoms such as urgency without infection. People in the low-risk tier who have a single mildly positive marker and an obvious benign explanation are the ones most often asked to repeat testing first.

Where you sit in this framework is a conversation, not a formula. The table describes what guidelines suggest; your own history may move you up or down, and that judgment belongs to your treating team.

What actually happens during a cystoscopy

Cystoscopy is the reference standard for looking at the bladder because, unlike any marker or scan, it shows the lining directly. A cystoscope is a thin tube with a light and camera at the tip, passed through the urethra (the channel urine leaves through) into the bladder.

There are two kinds. A flexible cystoscopy uses a bendable scope about the width of a pencil and is done awake in an outpatient room, with numbing gel applied to the urethra. According to the Mayo Clinic, a simple outpatient cystoscopy takes around 5 to 15 minutes. A rigid cystoscopy uses a straight scope under general or spinal anesthesia in an operating room and is chosen when the surgeon expects to take biopsies or remove tissue; the Mayo Clinic gives a typical range of 15 to 30 minutes for the procedure itself.

For a flexible cystoscopy, the sequence is usually this. You empty your bladder and provide a sample to check for infection. You lie on your back with knees bent. The clinician cleans the area, applies the numbing gel and waits a few minutes for it to work. The scope is passed slowly; most people describe pressure and a strong urge to pass urine rather than sharp pain. Sterile fluid is run in to unfold the bladder so every wall can be seen. If a suspicious area is spotted, a small biopsy can sometimes be taken through the flexible scope; larger or more numerous lesions are booked for the rigid procedure.

Both the NHS and the Mayo Clinic describe the common after-effects as a burning sensation on passing urine, needing to go more often, and a little blood, usually settling within a day or two. Drinking normally helps flush the bladder. Infection is the main complication to watch for, and the signs are listed in the “When to call your doctor” section.

A normal cystoscopy carries real weight. It does not make a positive marker disappear, but it removes the most serious explanation from the front of the queue.

Which imaging is used, and why the camera alone is not enough

A cystoscope sees the bladder and the last stretch of the urethra. It cannot see the ureters (the two tubes carrying urine down from the kidneys) or the kidneys’ collecting systems, yet those are lined with the same urothelial cells and can harbor the same tumors, as well as stones and other causes of bleeding. Imaging fills that gap.

CT urography is a CT scan performed with intravenous contrast and timed so that the dye is being excreted through the kidneys and ureters when the images are taken. It shows stones, masses, blockages and structural abnormalities in one study and is the guideline-recommended choice for people in the high-risk tier. It involves ionizing radiation and requires adequate kidney function to handle the contrast, which is why blood tests are checked beforehand.

Kidney (renal) ultrasound uses sound waves, no radiation and no contrast. It is good at showing kidney masses, swelling from blockage and larger stones, but it cannot reliably see small lesions inside the ureter. Guidelines favor it for lower-risk individuals, in pregnancy, and when contrast is unsafe.

MR urography uses magnetic resonance imaging and is an alternative when radiation must be avoided or when CT contrast cannot be given. It is slower, less widely available and less sensitive for small stones.

Retrograde pyelography is done during a rigid cystoscopy: contrast is injected up each ureter through the scope and X-ray images are taken. It is reserved for cases where other imaging is inconclusive or impossible.

A practical point people appreciate knowing in advance: imaging and cystoscopy are often scheduled separately and in either order. Having the scan first does not mean something was found; it usually reflects scheduling and the desire to have every piece of information available when the urologist looks inside. The results are then read together, because a finding on one frequently changes how the other is interpreted.

Urine cytology atypical cells: what repeat testing can and cannot settle

Cytology reports use a standardized vocabulary, and one word in it causes more anxiety than any other: “atypical.” It means the pathologist saw cells that were not clearly normal but did not meet the criteria for suspicious or malignant. Inflammation, stones, recent instrumentation and previous bladder treatments all produce atypical cells, and so do early cancers. The category is a genuine gray zone, not a soft way of saying cancer.

MedlinePlus lists the standard result categories in ascending order of concern: negative, atypical, suspicious and positive for malignancy. Cytology is best at detecting high-grade urothelial cancer, the aggressive kind that sheds obviously abnormal cells. It is comparatively weak at picking up low-grade tumors, whose cells look close to normal under the microscope. That is the key to using it sensibly.

• A negative cytology after a positive protein or DNA marker is reassuring about high-grade disease but does not exclude a low-grade tumor. A cystoscopy usually still follows, because low-grade tumors are precisely what the camera is good at seeing.
• An atypical cytology is typically repeated after any infection has been treated, and combined with cystoscopy and imaging. Persistent atypia with a normal camera view may prompt closer surveillance or additional testing of the upper tract.
• A suspicious or positive cytology with a normal cystoscopy raises the possibility of disease that is flat and hard to see, or that sits in the ureters or kidney. Enhanced-view cystoscopy, random biopsies or upper-tract imaging and sampling may be discussed.

Repeat testing therefore answers a narrow question: is the abnormality persistent once the obvious confounders are removed? It cannot by itself tell you that the bladder is clear. Anyone told “we’ll just repeat the urine test” is entitled to ask what result would trigger a cystoscopy, and how soon. Most urologists will have a clear answer, and the conversation itself is part of good care.

Positive urine biomarker next steps when you have had bladder cancer before

The same result means something different in someone under surveillance for previous bladder cancer. Non-muscle-invasive bladder cancer, the most common form, has a strong tendency to come back in the bladder lining, which is why follow-up involves regular cystoscopies for years. Urine markers are used in this setting as an adjunct: a tool that may catch a recurrence between camera checks or raise the index of suspicion when the camera view is equivocal.

The AUA microhematuria guideline states that biomarkers should not replace cystoscopy for initial evaluation, and non-muscle-invasive bladder cancer guidelines take a similarly cautious view for surveillance, describing markers as optional additions rather than substitutes. In practice, a positive marker during surveillance commonly leads to:

• Bringing forward the next scheduled cystoscopy rather than waiting for the routine interval.
• Using enhanced-view techniques during that cystoscopy, such as blue-light or narrow-band imaging, which highlight flat lesions that ordinary white light can miss.
• Cytology on the same visit, and sometimes selective sampling of urine from each ureter to localize the source.
• Upper-tract imaging if the bladder looks clear, since people with previous bladder cancer have a higher-than-average chance of tumors in the ureters or kidney lining.

There is an added wrinkle. Treatments instilled into the bladder after tumor removal, including immunotherapy with bacillus Calmette-Guérin (a weakened bacterium that provokes an immune response against tumor cells) and intravesical chemotherapy, cause inflammation that can keep markers and cytology abnormal for months. Your team will factor in how recently you finished treatment when reading a positive result.

None of this alters the underlying message. The marker is a prompt to look, not proof of recurrence. People in surveillance often describe living with a low background hum of worry between checks; a positive marker turns the volume up, and the fastest way to turn it back down is a scheduled, thorough look inside rather than another round of urine testing.

What the following days and weeks usually look like

Timelines vary with local scheduling and your risk tier, but the shape of the pathway is fairly consistent, and knowing it in advance removes some of the unpredictability.

The first week or two. You are usually contacted about the result and, if infection is possible, asked for a further sample. If a benign cause is confirmed and treated, the guideline approach is to re-test once it has cleared before deciding on anything more. If no benign cause is found, or you fall into a higher-risk tier, referral to urology proceeds directly. In the UK, the NHS advises that visible blood in the urine warrants prompt assessment by a general practitioner, who arranges urgent specialist referral where indicated.

Before the appointment. Expect blood tests for kidney function if CT with contrast is planned, and a request to bring a list of medicines, particularly blood thinners, because biopsy plans depend on them. Do not stop any prescribed medicine on your own account; your prescribing clinician will advise whether anything needs adjusting.

The cystoscopy and imaging visit. These may be on the same day or split across visits. The Mayo Clinic notes that side effects from a flexible cystoscopy, mainly burning, frequency and light bleeding, usually last 24 to 48 hours. Most people return to normal activities the same or next day.

Results. The urologist can generally tell you what the camera showed before you leave the room. Imaging reports and cytology take longer, typically days to a couple of weeks depending on the laboratory. If a biopsy was taken, pathology results follow on a similar schedule.

Afterward. Three broad outcomes exist. Everything is clear and a plan for any repeat testing is agreed. A benign cause is found and treated. Or a lesion is identified and the conversation shifts to what it is and what the options are. In each case, the next decision is made with you by your treating team, with the full set of findings in front of them.

What if the cystoscopy and imaging are both clear?

This is the outcome most people get, and it deserves a proper answer rather than a shrug. A normal cystoscopy and normal upper-tract imaging together carry a high negative predictive value for urinary tract cancer, which is a technical way of saying that when both are clear, cancer is unlikely at that point in time. The positive marker is then, by definition, most probably a false positive, or the signature of a benign process that has already resolved.

What happens next depends on whether blood in the urine persists. The AUA guideline suggests a repeat urinalysis within about 12 months after a negative evaluation. If the urine has returned to normal, no further routine urologic testing is generally needed. If microscopic blood persists, the guideline recommends a shared decision about whether to repeat the evaluation, taking into account whether new risk factors or symptoms have appeared. Persistent microscopic blood without a urologic cause is sometimes traced to the kidneys’ filtering units rather than the urinary tract, and a referral to a kidney specialist (nephrologist) may be considered, especially if protein is also present in the urine or blood pressure is raised.

Two questions come up repeatedly here. “Should the tumor marker itself be repeated?” Often it is not, because a repeat positive would not change management if the definitive tests were clear; the camera and scan outrank the marker. “Could something have been missed?” No test is perfect, but the combination described is what guidelines regard as the definitive evaluation, and the appropriate safety net is the planned repeat urinalysis plus a clear instruction to return early if visible blood, new pain or urinary symptoms develop.

Clinicians sometimes describe this as “closing the loop.” The loop is not closed by a reassuring conversation alone; it is closed by a written plan for what will be checked, when, and what would reopen the evaluation.

What people often get wrong about a positive urine biomarker

“Positive means I have cancer.” It does not. It means a substance crossed a threshold. Infection, stones, instrumentation and prostate enlargement all cross the same threshold. The tests are tuned to miss as little disease as possible, and the price is a meaningful rate of alarms in people who are well.

“A negative marker means I can skip the cystoscopy.” Guidelines say otherwise for anyone being evaluated for blood in the urine. Markers miss a proportion of cancers, particularly low-grade tumors, and cytology is known to be weak on exactly that group. The camera remains the reference test.

“A blood test would have been more accurate.” There is no validated blood test for bladder cancer in routine use. Urine is the fluid that actually touches the bladder lining, which is why it is tested.

“If they order a CT scan, they must have found something.” CT urography is standard for the high-risk tier regardless of what the camera shows, because it images parts the camera cannot reach. Ordering it is protocol, not a hint.

“Cystoscopy is agonizing.” Most people describe discomfort and a strong urge to urinate during a flexible cystoscopy, not severe pain. The NHS and the Mayo Clinic both describe it as usually well tolerated awake, with local anesthetic gel. Individual experience varies, and telling the clinician if it hurts is entirely appropriate.

“Newer DNA and RNA tests are accurate enough to replace all this.” They are improving, and some are used in surveillance to help decide the timing of camera checks. None has been endorsed by major guidelines as a stand-alone replacement for cystoscopy in initial diagnosis. When the evidence changes, the guidelines will, and until then a clinician who recommends the camera is following the evidence, not ignoring innovation.

“I can wait a few months and see.” For visible blood or a high-risk profile, delay is the one thing guidelines consistently advise against. Prompt evaluation is what keeps the range of options widest.

Questions to ask your care team

A ten-minute appointment goes further when you arrive with specific questions. These are the ones urologists say they are glad to be asked, grouped by the stage you are at.

When the result first comes through

• Which marker was positive, and is it an inflammation marker, a cell-based test or a DNA or protein tumor marker?
• Is there an obvious benign explanation in my case, such as infection, a stone or a recent procedure, and should it be re-tested once that has been addressed?
• Based on my age, smoking history and results, which risk tier do I fall into, and what does that mean for the tests you recommend?

Before cystoscopy and imaging

• Will my cystoscopy be flexible and awake, or rigid under anesthesia, and why that choice?
• Which imaging are you ordering, and does it involve contrast or radiation? Is there a reason to prefer ultrasound or MRI in my case?
• Do any of my current medicines, including blood thinners or supplements, need to be reviewed by the prescriber before a possible biopsy?
• Roughly how long after each test should I expect results, and how will I receive them?

After the results

• If everything is clear, what is the plan for repeat urinalysis, and what findings would reopen the evaluation?
• If cytology was atypical, will it be repeated, and what result would change the plan?
• If something was found, what are the next steps, what are the alternatives, and how much time do I have to think about them?

Write the answers down or bring someone who can. People routinely retain only a fraction of what is said in a stressful consultation, and a written plan is a fair thing to request. Every one of these questions has a reasonable answer; a team that welcomes them is a team you can work with.

When to call your doctor

Two situations call for prompt contact: symptoms that develop while you are waiting for evaluation, and problems in the days after a cystoscopy or biopsy.

While waiting for tests

• Visible blood in the urine, especially if new, heavier, or accompanied by clots. The NHS advises that visible blood should always be assessed, even a single episode.
• Inability to pass urine, or passing only small amounts with a painfully full bladder. This can be caused by clots blocking the outlet and is an emergency.
• Pain in the flank or lower back with fever, which can indicate infection above a blockage.
• New unexplained weight loss, persistent pelvic or bone pain, or swelling in the legs.

After a cystoscopy or biopsy

Mild burning, frequency and pink-tinged urine are expected and usually settle within 24 to 48 hours according to the Mayo Clinic. Contact your team the same day if you notice:

• Fever or chills, which may signal a urinary infection introduced during the procedure.
• Bleeding that gets heavier rather than lighter, or blood clots.
• Burning or pain that persists beyond two to three days or becomes severe.
• Inability to urinate.
• Severe abdominal or pelvic pain, nausea or vomiting.

Seek emergency care rather than waiting for a callback if you cannot pass urine at all, have heavy bleeding with dizziness or faintness, or have a high fever with shaking chills.

A final word on the space between tests. Waiting for results is often the hardest part of this whole process, harder for many than the procedures themselves. If anxiety is affecting sleep or daily life, say so; care teams can often speed up communication of results or connect you with support. Every decision along this pathway, from whether to repeat a test to what to do about a finding, rests with you and your treating team together, informed by the evidence described here rather than by the two words on a screen that started it all.

Frequently asked questions

What is a urine biomarker test and how is it different from a normal urine test?

A urine biomarker test measures a specific substance linked to a disease process, whereas a standard urinalysis screens broadly for blood, protein, glucose, nitrite and white cells. Tumor-related biomarker tests look at shed cells (cytology), particular proteins, chromosome changes or RNA patterns. A standard urinalysis often leads to a biomarker test rather than replacing it.

What are some common biomarkers found in urine?

The most common are red and white blood cells, leukocyte esterase, nitrite, protein or albumin, glucose and ketones, all measured on routine urinalysis. Kidney-focused markers include the albumin-to-creatinine ratio and urinary casts. Tumor-associated markers include cytology, nuclear matrix protein 22, bladder tumor antigen, chromosome-based FISH tests and RNA panels such as PCA3 for the prostate.

What cancers can be detected in urine?

Urine testing is mainly validated for urothelial cancers, meaning cancers of the bladder lining, ureters and kidney collecting systems, and as a risk-assessment aid for prostate cancer alongside the PSA blood test. Kidney cell cancers shed very little into urine and are usually found by imaging. Urine tests are not established screening tools for most other cancers.

What inflammation markers can be found in a urine test?

White blood cells and leukocyte esterase, an enzyme released by white cells, are the standard inflammation markers on urinalysis, usually alongside nitrite as a sign of bacteria. Research and some specialist settings also measure proteins such as NGAL or kidney injury molecule-1 for early kidney injury, but these remain largely investigational and are not part of routine cancer evaluation.

How likely is a urine biomarker false positive?

Common enough that guidelines do not allow biomarkers to substitute for cystoscopy. The tests are tuned to catch as much disease as possible, so they inevitably flag some healthy people. Infection, stones, prostate enlargement, recent instrumentation and previous bladder treatments are the usual culprits. Exact rates vary by test and population, which is why your clinician will interpret the result alongside your history.

Do I always need a cystoscopy after an abnormal urine test?

Not always, but usually for anyone with visible blood or an intermediate or high risk profile. The AUA microhematuria guideline allows a shared decision for low-risk adults between repeating urinalysis in about six months and proceeding directly to cystoscopy with ultrasound. A positive tumor marker generally pushes the decision toward cystoscopy, but the final call rests with your urology team.

What does 'urine cytology atypical cells' mean?

It means the pathologist saw cells that were not clearly normal but did not meet criteria for suspicious or malignant. Inflammation, stones, recent procedures and prior bladder treatments frequently cause atypia, and so can early cancer. The usual response is to treat any infection, repeat the cytology, and proceed with cystoscopy and imaging rather than relying on the urine result alone.

Is a cystoscopy painful?

Most people describe a flexible cystoscopy as uncomfortable rather than painful, with pressure and a strong urge to urinate while the scope is in place. Numbing gel is applied first and the procedure typically takes about 5 to 15 minutes according to the Mayo Clinic. Burning and frequency afterward usually settle within a day or two. Rigid cystoscopy is done under anesthesia.

Why do I need a CT scan if the cystoscopy was normal?

Because the camera only sees the bladder and urethra, not the ureters or the kidneys’ collecting systems, which share the same lining and can harbor tumors or stones. For people in the high-risk tier, CT urography is standard alongside cystoscopy regardless of what the camera shows. Ordering it reflects protocol, not a hidden finding.

What happens if everything is clear but blood is still in my urine?

The AUA guideline suggests a repeat urinalysis within about 12 months after a negative evaluation. If microscopic blood persists, you and your team decide together whether to repeat cystoscopy and imaging, taking into account new symptoms or risk factors. Persistent blood, particularly with protein or high blood pressure, may prompt referral to a kidney specialist to look at the kidney’s filtering units.

References

• Cystoscopy (NHS)
• Blood in urine (NHS)
• Urine cytology (MedlinePlus Medical Encyclopedia)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.